Literature DB >> 11286712

Viral vectors for dendritic cell-based immunotherapy.

L Jenne1, G Schuler, A Steinkasserer.   

Abstract

Transduction of dendritic cells (DCs) by viral vectors genetically engineered to express tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction allows the control of DC quality, antigen quantity and site of DC reinjection. This review evaluates the viral vectors currently being developed for use in DC-based immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11286712     DOI： 10.1016/s1471-4906(00)01813-5

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  31 in total

1.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

3.  Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Authors:  Andreas Pichlmair; Sandra S Diebold; Stephen Gschmeissner; Yasuhiro Takeuchi; Yasuhiro Ikeda; Mary K Collins; Caetano Reis e Sousa
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 4.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Authors:  David W O'Neill; Nina Bhardwaj
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

5.  Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Authors:  Karin Loré; William C Adams; Menzo J E Havenga; Melissa L Precopio; Lennart Holterman; Jaap Goudsmit; Richard A Koup
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

Review 6.  Directing dendritic cell immunotherapy towards successful cancer treatment.

Authors:  Rachel Lubong Sabado; Nina Bhardwaj
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

7.  Establishment of an electroporation-mediated gene delivery system in porcine spermatogonial stem cells.

Authors:  Min Seong Kim; Min Hee Park; Ji Eun Park; Jung Im Yun; Jung Hoon Choi; Eunsong Lee; Seung Tae Lee
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-02-06       Impact factor: 2.416

Review 8.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA.

Authors:  Nada M Melhem; Sherrianne M Gleason; Xiang Dong Liu; Simon M Barratt-Boyes
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

10.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.

Authors:  Bei Wang; Jin He; Chen Liu; Lung-Ji Chang
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.